Sign in
GENE Stock Price, Chart, Stats & News
Genetic Technologies Limited
Save
Genetic Technologies Limited (GENE) does not currently pay a dividend.
–
Market cap
–
Current P/E
–
Forward P/E
GENE chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 50.94% |
Operating margin | -159.30% |
Pretax margin | -156.78% |
Net margin | -156.78% |
Effective tax rate | – |
ROA | -194.25% |
ROE | -184.98% |
D/E | 0.48x |
Interest coverage ratio | -236.53x |
GENE valuation
P/E | – |
P/S | 21.10x |
P/B | 2.80x |
P/CF | -0.53x |
P/FCF | -16.65x |
P/OCF | -0.53x |
PEG | -0.00x |
EV multiple | -14.16x |
About
Genetic Technologies Limited (GENE) is a molecular diagnostics company specializing in providing predictive testing and assessment tools. These solutions empower healthcare professionals to better manage women's health concerns in both Australia and the United States. Its flagship product, BREVAGenplus, is a clinically validated risk assessment test specifically designed for non-hereditary breast cancer.
Similar securities
Based on sector and market capitalization
Report issue